On September 14, 2021 Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development reported their participation at the Bio-IT World Conference & Expo occurring virtually and in Boston, MA September 20-22, 2021 (Press release, Applied BioMath, SEP 14, 2021, View Source;expo-301376645.html [SID1234587699]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
John Burke, PhD, Co-founder, President and CEO of Applied BioMath will present "Applied BioMath Assess – An Early Feasibility Assessment Tool for Biotherapeutics" within the Software Applications and Services track on Tuesday, September 21st at 10:30 a.m. ET. In this presentation, Dr. Burke will demonstrate Applied BioMath Assess*, an interactive, web-based application that helps assess the difficulties and risks in developing a therapeutic very early-on. Dr. Burke will explain how Applied BioMath Assess can help project teams answer questions such as:
How does affinity impact target inhibition? Will it impact TMDD if membrane bound?
How does dosing interval impact success criteria?
How does target expression, especially in the site of action, impact design criteria?
How to think about therapeutic index prior to Lead Generation?
"Applied BioMath Assess provides rational go/no-go guidance while also helping project teams manage their resources efficiently," said Dr. Burke. "Our software has an exciting roadmap and will continue to evolve as we add new drug modality models and tools to best inform therapeutic R&D."
Additionally, Sharvari Gujja, Senior Principal Scientist, Bioinformatics at Applied BioMath will present a poster titled, "Leveraging ML/AI Tools for Robust Identification of Potential Biomarkers in Drug Response." The poster provides an overview of Applied BioMath’s open source, easy-to-use and flexible command line interface (CLI) to access the state-of-the-art Machine Learning and Deep Learning frameworks to build predictive models for assessing cancer drug response using gene expression data from The Cancer Genome Atlas Program (TCGA) and Genomics of Drug Sensitivity in Cancer (GDSC).